HELLS and triple-negative breast carcinoma: In agreement with the PARPi sensitivity that we observed, the HELLS gene was identified in a genome-wide shRNA screen for olaparib sensitivity, and as part of a gene signature associated with response to PARP inhibition in a panel of triple-negative breast cancer cell lines (70,71).